Trial Profile
A study evaluating infections in patients receiving Ibrutinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association